drugset / Trial / NCT04939857

Effect of Trimetazidine on Radiotherapy-induced Heart Damage.

NCT04939857

Phase 2/3 Unknown 80 enrolled Peking University Third Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized controlled trial. 80 patients with thoracic radiotherapy will be included. Participants will be randomly divided into experimental group or control group. Before radiotherapy, echocardiography, 2D STE, CK, CK-MB, cTnT, NT-proBNP, electrocardiogram (ECG), and hs-CRP will be detected. During subsequent follow-up, echocardiography, 2D STE, CK, CK-MB, cTnT, NT-proBNP, ECG, and hs-CRP will be collected at every follow-up time.

Timeline

Start
2021-06-25
Primary completion
2022-07-30
Completion
2022-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Trimetazidine Small molecule 20 mg

Indications